Robert Nathaniel Lande Sells 15,000 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUDGet Free Report) Director Robert Nathaniel Lande sold 15,000 shares of the stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of C$5.91, for a total transaction of C$88,600.50.

Knight Therapeutics Trading Down 3.7 %

Shares of TSE:GUD opened at C$5.79 on Friday. Knight Therapeutics Inc. has a 12-month low of C$4.35 and a 12-month high of C$6.22. The company has a market capitalization of C$586.99 million, a PE ratio of -36.19, a PEG ratio of -1,013.50 and a beta of 0.46. The business has a 50 day moving average of C$5.76 and a two-hundred day moving average of C$5.52. The company has a current ratio of 3.34, a quick ratio of 1.79 and a debt-to-equity ratio of 9.20.

Knight Therapeutics (TSE:GUDGet Free Report) last announced its earnings results on Thursday, March 21st. The company reported C($0.03) earnings per share for the quarter, missing the consensus estimate of C$0.02 by C($0.05). The business had revenue of C$74.20 million for the quarter, compared to analyst estimates of C$78.37 million. Knight Therapeutics had a negative return on equity of 2.21% and a negative net margin of 5.25%. As a group, analysts forecast that Knight Therapeutics Inc. will post 0.0303448 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on GUD. Raymond James lifted their target price on Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an “outperform” rating in a research report on Wednesday, March 6th. Stifel Nicolaus boosted their price target on Knight Therapeutics from C$5.40 to C$5.75 in a research note on Friday, May 10th. Finally, Royal Bank of Canada lifted their target price on Knight Therapeutics from C$6.50 to C$7.00 and gave the stock an “outperform” rating in a report on Friday, March 22nd.

Get Our Latest Analysis on Knight Therapeutics

About Knight Therapeutics

(Get Free Report)

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.

Read More

Insider Buying and Selling by Quarter for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.